About Allena Pharmaceuticals (NASDAQ:ALNA)
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577
Debt
Debt-to-Equity Ratio0.07%
Current Ratio12.74%
Quick Ratio12.74%
Price-To-Earnings
Trailing P/E Ratio-2.85
Forward P/E Ratio-6.74
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.01 per share
Price / Book3.41
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees34
Outstanding Shares20,700,000
Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions
What is Allena Pharmaceuticals' stock symbol?
Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How were Allena Pharmaceuticals' earnings last quarter?
Allena Pharmaceuticals (NASDAQ:ALNA) announced its earnings results on Tuesday, March, 27th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.06. View Allena Pharmaceuticals' Earnings History.
What price target have analysts set for ALNA?
5 equities research analysts have issued twelve-month price targets for Allena Pharmaceuticals' shares. Their forecasts range from $21.00 to $61.00. On average, they expect Allena Pharmaceuticals' share price to reach $35.25 in the next year. View Analyst Ratings for Allena Pharmaceuticals.
What are Wall Street analysts saying about Allena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (2/13/2018)
- 2. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)
Who are some of Allena Pharmaceuticals' key competitors?
Some companies that are related to Allena Pharmaceuticals include Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Solid Biosciences (SLDB), Vericel (VCEL), Nightstar Therapeutics (NITE), Agenus (AGEN), Cellular Biomedicine Gr (CBMG), Idera Pharmaceuticals (IDRA), Adverum Biotechnologies (ADVM), NantKwest (NK), Osiris Therapeutics (OSIR), Fennec Pharmaceuticals (FENC), NanoString Technologies (NSTG) and Arsanis (ASNS).
Who are Allena Pharmaceuticals' key executives?
Allena Pharmaceuticals' management team includes the folowing people:
- Dr. Alexey L. Margolin Ph.D., Co-Founder, CEO & Director (Age 65)
- Dr. Louis Brenner, Pres & COO (Age 48)
- Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 58)
- Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 53)
- Mr. Hugh Wight, VP of Technical Operations
When did Allena Pharmaceuticals IPO?
(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does Allena Pharmaceuticals' lock-up period expire?
Allena Pharmaceuticals' lock-up period expires on Tuesday, May 1st. Allena Pharmaceuticals had issued 5,333,333 shares in its IPO on November 2nd. The total size of the offering was $74,666,662 based on an initial share price of $14.00. After the expiration of Allena Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Has Allena Pharmaceuticals been receiving favorable news coverage?
Press coverage about ALNA stock has trended somewhat positive on Monday, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allena Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also gave media headlines about the company an impact score of 45.96 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Allena Pharmaceuticals?
Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allena Pharmaceuticals' stock price today?
One share of ALNA stock can currently be purchased for approximately $13.68.
How big of a company is Allena Pharmaceuticals?
Allena Pharmaceuticals has a market capitalization of $287.25 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.
How can I contact Allena Pharmaceuticals?
Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.
MarketBeat Community Rating for Allena Pharmaceuticals (ALNA)
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Allena Pharmaceuticals (NASDAQ:ALNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Allena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $35.25, suggesting that the stock has a possible upside of 157.68%. The high price target for ALNA is $61.00 and the low price target for ALNA is $21.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $35.25 | $24.6667 | $24.6667 | N/A |
| Price Target Upside: | 157.68% upside | 249.88% upside | 140.65% upside | N/A |
Allena Pharmaceuticals (NASDAQ:ALNA) Consensus Price Target History
Allena Pharmaceuticals (NASDAQ:ALNA) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Allena Pharmaceuticals (NASDAQ:ALNA) Earnings History and Estimates Chart
Allena Pharmaceuticals (NASDAQ:ALNA) Earnings Estimates
2018 EPS Consensus Estimate: ($1.50)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q2 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q3 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
Allena Pharmaceuticals (NASDAQ ALNA) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/27/2018 | Q4 2017 | ($0.54) | ($0.48) | | | View | N/A |  |
| 12/14/2017 | Q3 2017 | ($0.38) | ($3.49) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Allena Pharmaceuticals (NASDAQ:ALNA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Allena Pharmaceuticals (NASDAQ ALNA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 84.13%
Allena Pharmaceuticals (NASDAQ ALNA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/6/2017 | Bessemer Venture Partners Vii | Major Shareholder | Buy | 36,000 | $14.00 | $504,000.00 | | |
| 11/6/2017 | James N Topper | Director | Buy | 500,000 | $14.00 | $7,000,000.00 | | |
(Data available from 1/1/2013 forward)
Allena Pharmaceuticals (NASDAQ ALNA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
finance.yahoo.com - April 21 at 9:11 AM |
 | Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 13 at 5:21 AM |
| Allena Pharmaceuticals (ALNA) Enters Overbought Territory
finance.yahoo.com - April 4 at 4:55 PM |
| Allena Pharmaceuticals Inc (ALNA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 3:38 PM |
| Roth Capital Begins Coverage on Allena Pharmaceuticals (ALNA)
www.americanbankingnews.com - April 2 at 9:34 AM |
| Allena Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.38) Per Share (ALNA)
www.americanbankingnews.com - March 30 at 6:50 AM |
| Allena Pharmaceuticals (ALNA) PT Lowered to $21.00
www.americanbankingnews.com - March 28 at 10:48 AM |
| Allena Pharmaceuticals (ALNA) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 28 at 10:48 AM |
| Allena Pharmaceuticals (ALNA) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 28 at 9:16 AM |
| Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 27 at 9:45 AM |
| Zacks: Brokerages Expect Allena Pharmaceuticals Inc (ALNA) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - March 27 at 5:21 AM |
| ValuEngine Upgrades Allena Pharmaceuticals (ALNA) to "Sell"
www.americanbankingnews.com - March 25 at 9:16 PM |
| Allena Pharmaceuticals Inc (ALNA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 4:17 PM |
| -$0.27 Earnings Per Share Expected for Allena Pharmaceuticals Inc (ALNA) This Quarter
www.americanbankingnews.com - March 9 at 11:08 PM |
| Allena Pharmaceuticals' (ALNA) "Buy" Rating Reiterated at Wedbush
www.americanbankingnews.com - March 9 at 4:54 PM |
 | State’s biotech IPO class of 2017 gets mixed reviews from investors
www.bizjournals.com - March 8 at 9:40 AM |
 | Allena Pharmaceuticals (ALNA) Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric
www.streetinsider.com - March 7 at 5:23 PM |
| Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:28 AM |
| Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
finance.yahoo.com - March 6 at 9:13 AM |
| Frazier Management LLC Purchases New Stake in Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - March 5 at 8:00 AM |
| Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?
finance.yahoo.com - February 23 at 5:02 PM |
| Allena Pharmaceuticals Inc (ALNA) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - February 21 at 5:22 AM |
| Pharmstandard International S.A. Buys Allena Pharmaceuticals Inc
finance.yahoo.com - February 15 at 8:39 AM |
| Jefferies Group Weighs in on Allena Pharmaceuticals Inc's FY2017 Earnings (ALNA)
www.americanbankingnews.com - February 15 at 7:56 AM |
| Allena Pharmaceuticals Inc (ALNA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 5:52 PM |
| Allena Pharmaceuticals (ALNA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 13 at 4:16 PM |
| Wedbush Comments on Allena Pharmaceuticals Inc's FY2022 Earnings (ALNA)
www.americanbankingnews.com - February 9 at 6:30 PM |
| Analysts Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - February 1 at 1:28 AM |
| Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - January 18 at 7:14 AM |
| Brokerages Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 17 at 5:42 AM |
| Zacks: Analysts Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 2 at 9:42 PM |
| Comparing Allena Pharmaceuticals (ALNA) & The Competition
www.americanbankingnews.com - December 20 at 9:28 PM |
| Wedbush Equities Analysts Increase Earnings Estimates for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - December 20 at 9:56 AM |
| Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (ALNA)
www.americanbankingnews.com - December 18 at 8:26 PM |
| Brokerages Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - December 15 at 5:52 AM |
| Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - December 14 at 8:12 AM |
| Allena Pharmaceuticals, Inc.'s Quiet Period To End on December 12th (NASDAQ:ALNA)
www.americanbankingnews.com - December 5 at 1:32 AM |
| Equities Analysts Offer Predictions for Allena Pharmaceuticals, Inc.'s Q3 2017 Earnings (ALNA)
www.americanbankingnews.com - November 30 at 5:58 AM |
| Allena Pharmaceuticals, Inc. (ALNA) Forecasted to Earn Q3 2017 Earnings of ($0.30) Per Share
www.americanbankingnews.com - November 29 at 7:34 AM |
| Zacks: Allena Pharmaceuticals, Inc. (ALNA) Given $22.00 Average Price Target by Analysts
www.americanbankingnews.com - November 28 at 9:24 AM |
| Allena Pharmaceuticals, Inc. (ALNA) Now Covered by Analysts at Jefferies Group LLC
www.americanbankingnews.com - November 27 at 6:50 PM |
| Allena Pharmaceuticals, Inc. (ALNA) Coverage Initiated at Wedbush
www.americanbankingnews.com - November 27 at 8:36 AM |
| Cowen Inc Initiates Coverage on Allena Pharmaceuticals, Inc. (ALNA)
www.americanbankingnews.com - November 27 at 8:36 AM |
| Allena Pharmaceuticals, Inc. (ALNA) Receives New Coverage from Analysts at Credit Suisse Group
www.americanbankingnews.com - November 27 at 7:58 AM |
| Allena Pharmaceutical's stock falls in its public debut
finance.yahoo.com - November 24 at 2:48 PM |
| Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check
finance.yahoo.com - November 24 at 2:48 PM |
| What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?
finance.yahoo.com - November 24 at 2:48 PM |
| Allena Pharmaceuticals Inc (ALNA) Major Shareholder Bessemer Venture Partners Vii Buys 36,000 Shares
www.americanbankingnews.com - November 6 at 9:20 PM |
| Allena Pharmaceuticals Inc (ALNA) Director James N. Topper Purchases 500,000 Shares
www.americanbankingnews.com - November 6 at 9:20 PM |
| Allena Pharmaceuticals (ALNA) Announces November 2nd IPO
www.americanbankingnews.com - October 25 at 1:04 AM |
Allena Pharmaceuticals (NASDAQ:ALNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Allena Pharmaceuticals (NASDAQ:ALNA) Income Statement, Balance Sheet and Cash Flow Statement
Allena Pharmaceuticals (NASDAQ ALNA) Stock Chart for Monday, April, 23, 2018
Loading chart…
